No quarterly revenue total was found in PROMIS NEUROSCIENCES INC.'s SEC filings.
Promis Neurosciences Inc. (PMN) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-11.73M
-15.9% vs year-ago quarter
Operating cash flow
$-10.39M
-169.4% vs year-ago quarter
Free cash flow
—
EPS
$-1.28
+82.4% vs year-ago quarter
Dividend per share
None
Shares outstanding
8.97M
-82.7% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PMN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Canada (Federal Level)
- Headquarters
- Toronto, Ontario, Canada
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1374339
- Former names
- AMORFIX LIFE SCIENCES LTD (until Nov 3, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$12.3M | -$8.6M | -$10.8M | -$11.8M | -$10.2M |
| Net income | -$11.7M | -$8.2M | -$10.7M | -$11.6M | -$10.1M |
| Diluted EPS | -$1.28 | -$1.26 | $0.10 | -$0.24 | -$7.26 |
| Operating cash flow | -$10.4M | -$12.4M | -$9.3M | -$10.1M | -$3.9M |
| Total assets | $56.7M | $67.4M | $9.2M | $21.5M | $9.5M |
| Total liabilities | $7.3M | $6.7M | $10.4M | $12.3M | $9.9M |
| Stockholders' equity | $49.4M | $60.7M | -$1.3M | $9.2M | -$382,578 |
| Cash and investments | $53.5M | $63.8M | $6.2M | $15.4M | $4.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jul 28, 2026 | Jul 28, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 20, 2026 | May 20, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 12, 2026 | May 12, 2026 |
All 373 Promis Neurosciences Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.